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Purpose: Little is known about adverse drug events (ADEs) experienced over time
during chronic drug use. The purpose of this study was to assess ADE patterns
experienced by patients with diabetes.
Methods: Patients who received an oral glucose‐lowering drug completed a daily
diary for 13 weeks. The diary asked for experienced symptoms and whether patients
related these symptoms to any drug they used. Summaries of Product Characteristics
were used to check whether the ADEs were known adverse drug reactions (ADRs) of
the drugs used. Patterns of weekly occurring ADEs were assessed with descriptive
statistics.
Results: We included 78 patients. Almost half of them reported at least one ADE
(N = 36; 46%). In total, 80 ADEs were reported. Of these ADEs, 71 (90%) were known
ADRs. ADEs lasted less than 1 week in 27 cases (34%) and between 2 and 12 weeks
in 15 cases (19%). The remaining ADEs fluctuated (16 cases; 20%) or persisted (22
cases; 28%) during the entire study period.
Conclusions: ADEs experienced by patients with diabetes can fluctuate or persist
over long periods of drug use.
KEYWORDS
diabetes mellitus, drug‐related side effects and adverse reactions, patients,
pharmacoepidemiology, primary health care, type 21 | INTRODUCTION
Possible adverse drug reactions (ADRs) reported by patients (in this
article referred to as adverse drug events [ADEs]) are common. We
previously found that 27% of diabetes patients experienced at least
one ADE in the past 4 weeks at a random moment of treatment
stage.
1
ADEs are most likely to occur at treatment start, that is, within
days or weeks after treatment initiation.
2-5
However, ADEs can also- - - - - - - - - - - - - - - - - - - - - - - - - -
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rug Safety Published by John Wiemerge during chronic treatment because of changes in the patient's
susceptibility or situation, such as a decrease in kidney function or a
drug–drug interaction.
6
In Europe, information about ADRs is provided in the Summary
of Product Characteristics (SmPC) of a drug. This may include
details about the frequency of the reaction and time of occurrence
after treatment initiation. Occasionally, information is provided on
the expected duration, for example, when reactions are usually- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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KEY POINTS
• Approximately half of the adverse drug events (ADEs)
reported by patients were fluctuating or persistent over
a period of 13 weeks, whereas a third of such ADEs
had a short duration of not more than 1 week.
• Health care providers should pay attention to fluctuating
and persistent ADE patterns in patients on chronic
medication.
2 DENIG ET AL.transient and expected to resolve within a short period of time.
Postmarketing studies have illustrated that some ADEs are experi-
enced by patients for a short time whereas others can persist during
treatment.2-4,7
More knowledge about ADE patterns over time is important for
guideline developers, drug regulators, and pharmaceutical industry.
This is also much needed to inform patients and health care
providers and help them to detect, mitigate, and deal with
ADEs better. Not knowing what to expect, ADEs may lead to
unneeded or unguided reduction or discontinuation of drugs. Our
aim was to assess ADEs as experienced over time by patients with
diabetes.2 | METHODS
2.1 | Design
A post hoc cohort study was conducted using diary data previously
collected for the validation of a patient‐reported ADE‐questionnaire.8
Informed consent was obtained from all participants.2.2 | Participants
Adults being dispensed at least one oral glucose‐lowering drug were
recruited via pharmacies in the north of the Netherlands. The dispens-
ing of this drug was used as proxy for a diagnose of type 2 diabetes.
No restrictions were made on treatment duration or concomitant
treatment, thereby including a heterogeneous group of patients.
Recruitment procedures have been described in detail previously.8
Patients were included if they could provide an e‐mail address, had
internet access, and returned a completed consent form. This recruit-
ment method implies that patients were using chronic medication at
the time of data collection, possibly including other drugs aside from
the oral glucose‐lowering drug, or could even start with a new drug
during follow‐up.2.3 | Data collection
Patients were asked to complete on a daily basis a paper‐based diary
for a period of 13 weeks. An open‐ended question asked for any
symptoms they had experienced each day. A follow‐up closed‐ended
question in the diary asked whether or not the patient thought the
symptom was related to medication use. There is a difference
between the definition of an ADR and an ADE in respect to whether
or not formal causality assessment is applied.9 The symptoms that
patients concerned to be possibly related to the use of their drugs
were considered as ADEs since no formal causality assessment was
done in this study. These ADEs were classified according to the Med-
ical Dictionary for Regulatory Activities System Organ Class (MedDRA
SOC).10 At the end of the period, patients completed a structured
questionnaire to collect background characteristics and informationabout the drugs they had used in the study period, including prescrip-
tion drugs and self‐medication.11
2.4 | ADE‐drug relation
All drugs the patient had reported to use were checked for known
ADRs as referred in the most recent SmPC identified through the
medicines information repository of the Dutch Medicines Evaluation
Board (https://www.geneesmiddeleninformatiebank.nl/en). Reported
ADEs that were identified in these SmPCs were documented as a pos-
sible ADE‐drug relation.
2.5 | ADE patterns
ADE patterns were described as occurring in each of the 13 weeks
during the study period. Occurrence could result in the following pat-
terns: (a) short ADE episode, an ADE was only reported in 1 of the
13 weeks; (b) intermediate ADE duration, an ADE was reported in at
least 2 but less than 13 consecutive weeks; (c) fluctuating pattern,
an ADE was reported during at least 2 nonconsecutive weeks; and
(d) persisting ADE, an ADE was reported in all 13 weeks.
2.6 | Statistical analysis
Descriptive statistics were used to describe the included population,
the occurrence of ADEs, possible ADE‐drug relations (ie, the number
of reported ADEs that are known in SmPCs of any of the drugs the
patients use), and ADE patterns (ie, the number of short, intermediate,
fluctuating, and persisting patterns).3 | RESULTS
Seventy‐eight patients completed the study. These patients were on
average 65 years old (SD: 9, range 42–82) and 47 (60%) were male.
Thirty‐six patients (46%) reported at least one ADE during the
13 weeks. In total, 80 ADEs were reported, most of which belonged
to gastrointestinal disorders, nervous system disorders, and musculo-
skeletal and connective tissue disorders (Table 1). Of the 36 patients
who reported an ADE, 19 (53%) also reported at least one symptom
TABLE 1 Frequency of ADE patterns per MedDRA System Organ Class (SOC)
MedDRA SOC level Total Number Short Intermediate Fluctuating Persisting
Blood & lymphatic system disorders 0
Cardiac disorders 1 1
Congenital, familial, & genetic disorders 0
Ear & labyrinth disorders 1 1
Endocrine disorders 0
Eye disorders 1 1
Gastrointestinal disorders 22 7 3 6 6
General disorders and administration site conditions 7 2 1 2 2
Hepatobiliary disorders 0
Immune system disorders 0
Infections & infestations 0
Injury, poisoning, & procedural complications 0
Investigations 0
Metabolism & nutrition disorders 2 1 1
Musculoskeletal & connective tissue disorders 13 3 5 2 3
Neoplasms benign, malignant, and unspecified (incl. cysts & polyps) 0
Nervous system disorders 14 7 2 1 4
Pregnancy, puerperium and perinatal conditions 0
Psychiatric disorders 3 1 2
Renal & urinary disorders 2 1 1
Respiratory, thoracic, & mediastinal disorders 3 3
Skin & subcutaneous tissue disorders 9 3 2 1 3
Social circumstances 0
Surgical and medical procedures 0
Vascular disorders 1 1
Not classifieda 1 1
Total number 80 27 15 16 22
Abbreviations: ADE, adverse drug event; MedDRA, Medical Dictionary for Regulatory Activities.
aOne ADE was not classified because of an unclear description of the ADE.
DENIG ET AL. 3during the 13 weeks, which they did not consider to be an ADE. Of
the 42 patients who did not report an ADE, 17 (41%) reported at least
one symptom in the diary.3.1 | ADE‐drug relation
Patients who reported an ADE used on average six drugs (range 1‐17).
For eight of the 80 ADEs, the patient used no drugs for which the
reported ADE was stated in the SmPC. For one ADE, a link with the
used drug was questionable given the patient's description of the
ADE. In all other cases (N = 72; 90%), patients used at least one drug
that had the reported ADE in the SmPC (Appendix S1). For example,
patients reporting musculoskeletal and connective tissue ADEs often
used statins, and patients reporting gastrointestinal ADEs often used
metformin. In many cases, patients used multiple drugs that had the
reported ADE as a known ADR.3.2 | ADE patterns
Of the 80 reported ADEs, 27 (34%) were short episodes of not more
than 1 week, 15 (19%) had an intermediate duration, 16 (20%) showed
a fluctuating pattern, and 22 (28%) persisted during the 13‐week
study period. Nervous system disorders had mostly a short episode,
whereas musculoskeletal and connective tissue disorders were mostly
of intermediate duration. For the gastrointestinal disorders, short epi-
sodes, fluctuating patterns, and persisting patterns were seen to a sim-
ilar extent (Table 1).
Short episodes were often ADEs reported for periods of 1 to
3 days and were most often reported in the first two study weeks.
The duration for intermediate ADEs ranged from 2 to 9 weeks,
and 6 (40%) were reported for the first time in the first week. In
most of the fluctuating patterns, the ADE was experienced at 1 to
3 days, whereas the number of weeks in which the ADE was
reported ranged from 2 to 12 with a median of 6 weeks. In four
4 DENIG ET AL.cases, the ADE was reported on more than 20 days in the study
period. Most of the persisting patterns were reported during 5 to
7 days in all weeks (Appendix S2).4 | DISCUSSION
Almost half of the patients reported at least one ADE during the 13
study weeks, with a total of 80 ADEs. The majority of the ADEs could
be identified as a known ADR of one or more of the drugs the patient
used. Most commonly, we observed short duration, fluctuating or per-
sistent gastrointestinal ADEs, short duration nervous system ADEs,
and intermediate duration musculoskeletal ADEs.
The percentage of patients reporting possible ADEs in our study is
relatively high compared with previous studies.1,2,11 This may in part
be due to the follow‐up period of 13 weeks, in which many short
ADE episodes can be detected. More than 30% of the ADEs were
for short episodes. The number may also be high because of the pro-
spective data collection using a diary. Many patients used multiple
drugs that can cause possible ADEs. It can therefore be difficult for
patients to attribute a symptom to the drugs they use. Keeping a diary
might help to clarify this. Timing relationships are important for
patients to assess possible ADEs.12 On the other hand, it could be that
patients were more active in keeping the diary in the first week of the
study. Several short episodes were reported in the first 2 weeks. This
could imply overreporting in the first weeks but also underreporting
after the first weeks. For future studies, it is advised to use electronic
diaries to be able to send reminders. This will reduce the chance of
underreporting. Remarkable, however, was the high percentage of
experienced ADEs that could be linked to one of the drugs the
patients were using. This suggests that patients were able to identify
symptoms that are related to a drug, although they may still attribute
unrelated symptoms to their drugs.
Prospective monitoring studies in patients starting new drugs have
shown that patients may continue to use a drug despite perceiving a
possible ADE and without taking further action.2-4 Our study adds to
this knowledge that patients on chronic medication may experience
persisting ADEs over periods of at least 13 weeks, whereas other ADEs
may come and go during considerable periods of drug use. Such fluctu-
ation of ADEs has been reported before by patients receiving drugs for
chronic heart failure.7 It indicates that patients are willing to accept a
wide range of symptomatic ADEs or are able to deal with such ADEs
and that experienced ADEs are not necessarily a reason for patients to
discontinue treatment.3 Future studies are needed to assess the influ-
ence of the experienced severity of the ADE on patterns and actions
taken by patients. Our study illustrates that patients are willing to pro-
vide information about the duration of ADEs, but there could be selec-
tion bias among the participants.13 In addition to prospective
monitoring studies, it would therefore be useful to collect information
aboutADEpatterns in randomized controlled trials. Ultimately, informa-
tion about ADE timing should be considered for inclusion in SmPCs.
An important strength of our study is that we used a daily diary for
patients to report possible ADEs. Although we are not sure whetherpatients completed the diary on a daily basis, the use of a diary
reduces recall problems. We asked patients to report any symptoms
and subsequently asked whether they thought the symptom was
related to any of the drugs they used. This was previously suggested
as a more reliable way to question patients about ADEs.11
The most important limitation is the small sample size in our study.8
Regarding age, the participants appear similar to the average primary
care diabetes population in the Netherlands but a higher proportion
of males was included. Furthermore, we did not have diary data on
lifestyle or medication changes, which may influence ADE patterns.
In conclusion, ADEs experienced by patients with diabetes can
fluctuate or persist over long periods of drug use. It is important that
health care providers are aware of this and try to monitor ADEs better
by regularly informing and asking their patients on chronic medication
about ADEs during routine visits.
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